Navigation Links
£5 million investment in personalized medicines to cut patient deaths
Date:9/5/2007

A 5 million investment in the development of personalised medicines at the University of Liverpool will see the introduction of treatments tailored for individual patients.

Liverpool research estimates that a quarter of a million people are admitted to hospital in the UK each year following adverse reactions to a variety of commonly prescribed drugs which costs the NHS an average of 466 million annually. Personalised medication is based on a patients unique genetic make-up, allowing clinicians to prescribe the correct drug to the patient at the correct dose to achieve the maximum benefit and minimise the risk of drug side-effects.

The University has been selected by the Department of Health to receive a 3 million NHS Chair in Pharmacogenetics the first and only such position in the country. Professor Munir Pirmohamed from the Universitys Department of Pharmacology has been appointed to the Chair and will pioneer a major initiative to establish the clinical evidence base for safe and effective medication based on a patients unique genetic make-up and other factors such as diet and smoking.

Professor Pirmohamed will lead a team of 11 scientists, researchers and nurses in identifying gene groups which dictate a patients positive or negative response to a drug. The multidisciplinary team will tap into the North Wests large patient base to collect genetic information to test against medication for illnesses such as epilepsy and asthma, which can be affected by a patients genetic make-up. The Chair will complement a 10 million Centre for Personalised Medicines being created at the University.

The research, which will be carried out in collaboration with the Royal Liverpool University Hospital, Royal Liverpool Childrens Hospital and other hospitals in the North West, will focus on areas of public health importance including:

  • Anticonvulsant therapy in epilepsy
  • Inhaled steroids in children with asthma
  • Acute coronary syndrome and variability in response to treatments
  • Non steroidal anti-inflammatory drug (NSAID)-induced peptic ulceration

Professor Pirmohamed said: The study of pharmacogenetics is vital to the public health of this country. One of our recent studies showed that at any one time the equivalent of more than seven 800-bed hospitals are taken up with the patients who have suffered the side effects of drugs they have been prescribed.

This new investment will allow Liverpool to tackle this problem by providing the evidence base that is necessary to revolutionise the way important illnesses are treated in the UK and worldwide.

It is important to note that the way we respond to drugs is determined not only by genetic factors but also by environmental factors such as our diet and if we smoke. Through this comprehensive research strategy, we will build up a very detailed clinical picture of each individual patient and link it to genetic profiles with the aim of maximising the efficacy and reducing the potential toxicity of treatments.

Minister for Health, Ben Bradshaw MP, said: I am delighted to announce the award of the contract to host the NHS Chair in Pharmacogenetics to the University of Liverpool. Pharmacogenetics has enormous potential to improve the effectiveness and safety of the treatment patients receive and this post will make a major contribution to both boosting research capacity and raising awareness of pharmacogenetics among NHS clinicians.

A further 2 million has been awarded to the University by The Wolfson Foundation toward the Centre for Personalised Medicines. The unique centre will accommodate the research activity of the Chair as well as cutting-edge equipment such as a state-of-the-art DNA archiving system. The archive will hold up to 300,000 DNA samples of patients and will sort and select samples via an automated robotic system, enabling high-throughput genotyping and analysis. Included in the archive will be rare samples from people who have experienced adverse drug reactions affecting the liver or skin.

Based in the Universitys Old Royal Infirmary, the new facility will accommodate the pharmacogenetics team who will work alongside partner NHS organisations to collect clinical information from patients in hospitals across the North West. The team will focus on several priority research areas including toxicity and efficacy of drugs used to treat infections such as HIV.

Philanthropic gifts from individuals and organisations are expected to generate a further 5 million towards new equipment and staff at the Centre. The Wolfson Centre for Personalised Medicines will open in 2009.


'/>"/>

Contact: Joanna Robotham
joanna.robotham@liv.ac.uk
44-015-179-42026
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Hundred million dollar gift for malaria institute
3. George Bush pledges 200 million dollars for AIDS relief
4. Over Six Million HIV Infected People In South Africa- Finds A Survey
5. Hope for 11 million children facing death from illnesses
6. The forgotten epidemic killing millions
7. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
8. Tanzanian Government Sanctions $20 Million For AIDS Arug
9. Grant of $7 million for Orissa Medical College from Japan
10. Merck to pay $ 253.5 million to Vioxx victim family
11. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Bacteria and fungi are probably not the first ingredients that come ... including the right microorganisms in your diet can actually improve health outcomes. And the good ... is the topic of a new peer-reviewed paper led by Maria Marco, ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO ... Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle ... Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis ... A type of groin injury, it occurs when the muscles around the pelvis ... in and around the lower torso, as well as accompanying tenderness and weakness. ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of ... professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes ... supply chain and value analysis professionals have a ‘seat at the table’ with ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Inc. , a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, ... Operating Officer, is scheduled to present a corporate overview at two ... BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 PM ... ... Leaders in Biotech Industry – Friday, April 7, 2017 at 11:20 ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was valued at ... registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent graft system ... market during the study period. Continue Reading ... ... ...
Breaking Medicine Technology: